|Dr. Mitchell H. Gold||Exec. Chairman & CEO||703.25k||N/A||1968|
|Dr. Stanford Peng||Pres and Head of R&D||650.83k||N/A||1971|
|Mr. Paul Rickey||Sr. VP, CFO & Corp. Sec.||489.79k||N/A||1979|
|Dr. Wayne R. Gombotz||Chief Technology Officer||N/A||N/A||1959|
|Dr. Kristine Swiderek Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Alpine Immune Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.